Pallas Health vs MedVi: Clinician Options, Price, and Support Compared
Quick verdict: For patients who want a clinician to choose between brand-name pens and a per-patient compounded option, Pallas Health stands out; for those who want the simplest promotional entry and 24/7 certified support for compounded semaglutide, MedVi is the clearer fit.
How Pallas Health vs MedVi differ at a glance
The two platforms both prescribe compounded GLP-1s via online clinician review, but they diverge on medication range, pricing structure, and support hours. Use this comparison to match your priorities against what each provider documents.
| Criteria | Pallas Health | MedVi |
|---|---|---|
| Starting price | $139 first month for compounded semaglutide | $179 first month promotional price for compounded semaglutide |
| Ongoing pricing | $597 every 12 weeks for semaglutide ($199/mo avg); tirzepatide $897/12 weeks ($299/mo avg) | Standalone month $299 after promo; three-month plan $649 (~$216/mo) |
| Medications offered | FDA-approved Wegovy, Ozempic, Zepbound and Mounjaro plus compounded semaglutide and tirzepatide | Clinically dosed compounded semaglutide only; no tirzepatide or branded options published |
| Clinical model and review | US-licensed clinician personalizes plan; eligibility determined by clinician review | Online clinician review with OpenLoop Health clinicians; clinicians retain prescribing discretion |
| Support and access | Care-team messaging and check-ins included; weekday care-team hours 9 AM–5 PM ET; asynchronous in most states | 24/7 support from certified medical professionals; no clinic visits needed |
| Regulatory note | Compounded medications are not FDA-approved | Compounded medications are not FDA-approved |
1. Medication options and clinician choice
Pallas Health documents both routes in one intake: FDA-approved brand-name GLP-1s such as Wegovy, Ozempic, Zepbound and Mounjaro, and clinician-personalized compounded semaglutide or tirzepatide prepared in the USA when a brand medication is not the right fit. MedVi focuses on clinically dosed compounded semaglutide and does not publish tirzepatide or branded options. If having brand-name pens as a possible outcome of the intake matters, Pallas Health is the only provider here that explicitly offers both routes.
See MedVi semaglutide promo from $179
2. Pricing structure and renewal cadence
Pallas advertises compounded semaglutide at $139 for the first month, then $597 every 12 weeks, which equates to a $199 per month average. Compounded tirzepatide starts at $179 first month, then $897 every 12 weeks ($299/mo avg). Pallas also lists cash-pay pricing for branded options. MedVi promotes a winter price of $179 for the first month including fast, free shipping, but notes the ongoing standalone month is $299 unless a multimonth plan is chosen. Preserve the promotional qualifier: MedVi’s $179 is a first-month promo and refills are locked in at the full price specified at checkout.
3. Support model and access to clinicians
MedVi highlights 24/7 support from certified medical professionals and a process that requires no clinic visits. Pallas includes provider care, ongoing check-ins and care-team messaging in its all-in plan price, but care-team hours are weekdays 9 AM to 5 PM ET and Pallas notes no emergency services. Both state that a US-licensed clinician determines eligibility and that clinicians may decline treatment when it is not right for a patient.
4. Shipping, membership, and practical details
Both providers advertise free or fast free shipping. Pallas says free expedited and discreet shipping on every plan and emphasizes no membership fee; MedVi says no membership or hidden fees for the promoted program but references membership options on some pages. Both platforms operate as cash-pay and do not bill insurance, and both recommend discussing FSA/HSA or Letter of Medical Necessity where applicable. Pallas notes compounded plans renew every 12 weeks which affects cancellation timing; MedVi documents multimonth plan options to lower per-month costs.
5. Safety and regulatory notes
Both sources explicitly state that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Pallas clarifies it does not manufacture or compound medications; compounding is done by US-licensed compounding pharmacies and the medication received may differ in appearance from site images. MedVi likewise states it does not produce compounded medications and that they may look different than portrayed. Both urge clinical discussion with providers about risks and benefits.
Conclusion: Pallas Health vs MedVi
In short, Pallas Health is designed for patients who want a clinician to choose between brand-name pens and compounded preparations and who prefer an all-in plan price with clinician care included. MedVi is positioned for people seeking a simple online intake, a promotional first-month price on compounded semaglutide, and round-the-clock certified support.
Choose one if…
- Choose Pallas Health if you want the option of brand-name GLP-1s or clinician-personalized compounded semaglutide or tirzepatide, an all-in plan price, and clinician review that can refund if treatment is not right for you.
- Choose MedVi if you want a promotional first-month entry for compounded semaglutide, a simple no-clinic online process, and 24/7 certified medical support with free shipping on the promo.
Primary keyword: Pallas Health vs MedVi
Ready to Compare Telehealth Providers?
Explore leading providers — physician-supervised, all-inclusive pricing, and free home delivery.
Compare All Providers →More comparisons
